CJC-1295 No DAC Research Guide
2mg · Research compound — not for human consumption
Research Overview
CJC-1295 No DAC, also referred to as Modified GRF(1-29), is a synthetic peptide analog of growth-hormone-releasing hormone (GHRH). It has been studied in preclinical and laboratory settings as a research compound for its short-duration interaction with pituitary GHRH receptors. This material is intended for laboratory research only and is not intended for human consumption.
Structural & Class Overview
A 29-amino-acid analog of the GHRH(1-29) fragment carrying amino-acid substitutions (commonly at positions 2, 8, 15, and 27) intended to increase resistance to enzymatic degradation. It lacks the Drug Affinity Complex (DAC) albumin-binding moiety, and reported research characterizations describe a comparatively short circulating half-life. Mechanistically it is classified as a GHRH-receptor agonist acting through the cAMP second-messenger pathway.
General Research Interest
Research interest includes GHRH-receptor binding and activation dynamics; cAMP-mediated signaling in pituitary somatotroph models; pulsatile growth-hormone release patterns in preclinical systems; comparative pharmacokinetics against DAC-modified analogs; and use as a laboratory reference compound in growth-hormone-axis studies.
Storage Considerations
Store the lyophilized research peptide cool and dark, and protect from light, heat, and moisture. Reconstituted material is generally handled under refrigeration for laboratory use. For research handling only; not for human use.
Testing & Quality Considerations
Quality considerations for research material include HPLC purity assessment, mass-spectrometry identity confirmation, and verification against a batch Certificate of Analysis (COA).
References
- CJC-1295 — Wikipedia
- Once-daily administration of CJC-1295 normalizes growth in the GHRH knockout mouse (Am J Physiol Endocrinol Metab)
References are provided for scientific context. Linked sources are independent and not affiliated with iNGEN MD.
